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Abstract
Background: The two available drugs for treatment of T. cruzi infection, nifurtimox and benznidazole (BZ), have potential
toxic side effects and variable efficacy, contributing to their low rate of use. With scant economic resources available for
antiparasitic drug discovery and development, inexpensive, high-throughput and in vivo assays to screen potential new
drugs and existing compound libraries are essential.
Methods: In this work, we describe the development and validation of improved methods to test anti-T. cruzi compounds in
vitro and in vivo using parasite lines expressing the firefly luciferase (luc) or the tandem tomato fluorescent protein
(tdTomato). For in vitro assays, the change in fluorescence intensity of tdTomato-expressing lines was measured as an
indicator of parasite replication daily for 4 days and this method was used to identify compounds with IC50 lower than that
of BZ.
Findings: This method was highly reproducible and had the added advantage of requiring relatively low numbers of
parasites and no additional indicator reagents, enzymatic post-processes or laborious visual counting. In vivo, mice were
infected in the footpads with fluorescent or bioluminescent parasites and the signal intensity was measured as a surrogate
of parasite load at the site of infection before and after initiation of drug treatment. Importantly, the efficacy of various
drugs as determined in this short-term (,2 weeks) assay mirrored that of a 40 day treatment course.
Conclusion: These methods should make feasible broader and higher-throughput screening programs needed to identify
potential new drugs for the treatment of T. cruzi infection and for their rapid validation in vivo.
Citation: Canavaci AMC, Bustamante JM, Padilla AM, Perez Brandan CM, Simpson LJ, et al. (2010) In Vitro and In Vivo High-Throughput Assays for the Testing of
Anti-Trypanosoma cruzi Compounds. PLoS Negl Trop Dis 4(7): e740. doi:10.1371/journal.pntd.0000740
Editor: Timothy G. Geary, McGill University, Canada
Received February 5, 2010; Accepted May 27, 2010; Published July 13, 2010
Copyright:  2010 Canavaci et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was funded by National Institutes of Health (NIH) grants R01-AI033106 and R01-AI082542 to RLT. The funders had no role in study design,
data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: tarleton@cb.uga.edu
. These authors contributed equally to this work.
Introduction
Chagas disease, caused by the protozoan parasite Trypanosoma
cruzi, is the leading cause of cardiac disease in many countries of
Latin America. The World Health Organization has estimated
that 16–18 million people are currently infected and 90 million are
at risk of acquiring the infection [1–2]. Both of the available
compounds for treatment, benznidazole (RadanilH, Roche, Rio de
Janeiro) and nifurtimox (LampitH, Bayer, Leverkusen), have
potential side effects, require long courses of treatment, and
exhibit variable efficacy [3–6]. Therefore, there is an urgent need
to discover new treatment options with reduced toxicity. Several
compounds have been proposed as new therapies for T. cruzi
infection, however, few have moved beyond the candidate stage.
The development of in vitro and in vivo high-throughput assays
for the screening of anti-T. cruzi compounds is essential.
Epimastigotes of T. cruzi can be easily obtained in abundance
from axenic culture and drug efficacy determined using a variety
of approaches, including manual, spectrophotometric [7–11] or
fluorometric [12–13] assessment of parasite growth. In addition to
the fact that these epimastigote-based assays may not truly reflect
the effectiveness of compounds on the life cycle stages of T. cruzi
that are present in mammals (the extracellular trypomastigotes and
intracellular amastigotes) [14], these assays may be laborious and
difficult to scale up for high-throughput screening (HTS) [15–16].
Assays to detect drug susceptibility of the more appropriate T. cruzi
life cycle stage, the intracellular amastigotes, have been modified
to use parasites expressing the Escherichia coli b-galactosidase gene
(lacZ) [15] and this assay has also recently been scaled up for HTS
[17]. However one downside of this method is that it is a single
endpoint assay requiring post-assay processing to interpret.
W i t hr e s p e c tt oi nv i v od r u gt e s t i n go fa n t i - T. cruzi
compounds, the vast majority of studies use a mouse model
system where the compounds are administered early in the
acute phase of the infection [18–20], with the main criteria of
treatment efficacy based on the suppression of acute parasit-
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or on the use of parasite detection techniques that frequently
yield negative results (i.e. fail to detecte parasies) even in the
absence of treatment [6,18,20–22].
In this study we describe the generation of T. cruzi parasite lines
that express either the firefly luciferase (luc) or the tandem tomato
fluorescent protein (tdTomato) and the use of these lines to
establish accurate and simple in vitro as well as in vivo systems to
screen and test anti-T. cruzi compounds. tdTomato red fluorescent
parasites were detectable by microscopy and flow cytometry and
their fluorescence intensity was easily quantified using a fluores-
cence plate reader. Moreover, the replication of epimastigotes or
amastigotes could be monitored at multiple time points over the
culture period rather than at endpoint, providing a more accurate
assessment of parasite growth kinetics. Bioluminescent as well as
fluorescent parasites were detectable via in vivo imaging after
infection in mice and their expansion was used to rapidly assess the
in vivo efficacy of anti-T.cruzi compounds. These results highlight
the use of the methods described here as powerful new tools for the
more rapid and efficient high-throughput screening of potential
trypanocidal drugs in vitro and in vivo.
Methods
Ethics Statement
All animal protocols were approved by the University of
Georgia Institutional Animal Care and Use Committee.
Parasites and culture procedures
Epimastigote forms of T. cruzi CL WT or tdTomato strain were
cultured at 27uC in supplemented liver digest-neutralized tryptose
(LDNT) medium as described previously [23]. After 3–4 days in
LDNT, epimastigotes were submitted to a stress in triatome
artificial urine (TAU) medium for 2 h [24]. Then, parasites were
incubated in TAU3AAG medium [24] for 6–7 days, at the end of
which the highest number of metacyclic trypomastigote was
generally obtained. Parasites were then incubated in complement-
active FBS to lyse the remaining epimastigotes (by complement
activity). Vero cell monolayer cultures were infected with
metacyclics to generate trypomastigotes to use in the amastigote
growth inhibition assays. Infected Vero cells were cultured in
RPMI 1640 medium with 10% fetal bovine serum (FBS) in a
humid atmosphere containing 5% CO2 at 37uC.
Generation of fluorescent (tdTomato) Trypanosoma cruzi
To generate T. cruzi parasites expressing tandem dimeric
tomato red fluorescent protein [25] we constructed a plasmid
using the expression vector pTrex as a backbone [26]. The
1464 bp tdTomato gene was generated by PCR amplification
using the primer set 59-AGAATTCATGGCGCCTAGGGT-
GAGC-39 (forward) and 59-TACGTCGACTTAGAGCTCGA-
TATCGACG-39 (reverse), and the pCTR2t vector as the template
[27]. The forward primer has an EcoRI site and the reverse
primer has a SalI site. This PCR fragment was digested and cloned
downstream of the rRNA gene promoter and the HX1 fraction
into EcoRI and SalI sites in the multi-cloning site of the pTREX
plasmid, generating the pTREX-tdTomato plasmid (Figure 1A).
Transgenic parasites were generated as previously described
[28]. A total of 1610
7 early-log epimastigotes were centrifuged at
1,620 g for 15 min and suspended in 100 ml Human T Cell
Nucleofector
TM Solution (Lonza, Cologne) at room temperature.
The resuspended parasites were then mixed with 10 mg DNA in a
total volume of 10 ml and electroporated using the program ‘‘U-
33’’ in an AMAXA Nucleofector Device (Lonza). The electropo-
rated parasites were then cultured in 25 cm
2 culture flasks
(Corning Incorporated, Lowell, MA) with 10 ml LDNT medium
and 300 mg/ml G418 was added at 24 h post-transfection.
Parasite cultures are monitored by flow cytometry frequently for
loss of fluorescence, and when necessary, sortedto remove non-
fluorescent contaminants using a MoFlo cytometer (DakoCytoma-
tion, Carpinteria, CA) with an Enterprise 631 laser tuned to
488 nm for excitation and an emission filter with a band pass of
570/40 nm. Multiple strains of T. cruzi (CL, Tulahuen, Brazil,
Colombiana and TCC) expressing the tdTomato protein were
generated and the CL tdTomato strain used in the experiment
shown here unless otherwise noted.
Generation of bioluminescent Trypanosoma cruzi
To generate bioluminescent T. cruzi parasites, we constructed a
plasmid based on Multi-Gateway technology (Invitrogen, Carls-
bad, CA). The vector pLew90b was modified to include the
Gateway cloning cassette by first inserting a new 62 bp multiple
cloning site (CCCGAG(AvaI)ACCGGTGTTAACGGGCC CT-
TCGAAGGTACCGAGCTCTTAATTAAGATATC(SpeI)AC-
TAGT) into pLew90b at the Ava I and Spe I sites downstream of
the Tc Beta Tubulin gene. The Multi-Gateway cloning cassette
was digested from the pDEST-R4R3 (Invitrogen, Carlsbad, CA)
plasmid using Pci I. A Klenow reaction was used to fill in the Pci I
overhang. The fragment was then digested with BsaHI and cloned
into pLew90b at HpaI/BstBI sites in the new multiple cloning site
to create the pLew90b-GW-T7 destination plasmid. The com-
bined T7 promoter and PARP splice acceptor site for the
luciferase gene was cloned into the pDONR-P4P1R plasmid
using a synthetic DNA construct in the pPCR-Script vector
(GeneArt, Burlingame, CA). This fragment was digested from the
pPCR-script vector with KpnI and Hind III (flanking sites
underlined) then recombined into the pDONR-P4P1R (Invitro-
gen, Carlsbad, CA) plasmid utilizing the Gateway (Invitrogen,
Carlsbad, CA) Att recombination sites (bold italics; GGTACC-
GGGGACAACTTTGTATAGAAAAGTTGGGAGCTCGTAA-
TACGACTCACTATAGGGCGAATTGGATCCTGCACGCG-
CCTTCGAGTTTTTTTTCCTTTTCCCCATTTTTTTCAAC-
TTGAAGACTTCAATTACACCAAAAAGTAAAATTCACAAG-
CAAGTTTGTACAAAAAAGCAGTCCCCAAGCTT) was digest-
Author Summary
The treatment of Trypanosoma cruzi infection (the cause of
human Chagas disease) remains a significant challenge. Only
two drugs, both with substantial toxicity, are available and
the efficacy of thesedugsis often questioned – in many cases
due to the limitations of the methods for assessing efficacy
ratherthantotruelackofefficacy.Forthesereasonsrelatively
few individuals infected with T. cruzi actually have their
infections treated. In this study, we report on innovative
methods that will facilitate the discovery of new compounds
for the treatment of T. cruzi infection and Chagas disease.
Utilizing fluorescent and bioluminescent parasite lines, we
have developed in vitro tests that are reproducible and facile
and can be scaled for high-throughput screening of large
compound libraries. We also validate an in vivo screening test
that monitors parasite replication at the site of infection and
determines the effectiveness of drug treatment in less than
two weeks. More importantly, results in this rapid in vivo test
show strong correlations with those obtained in long-term
(e.g. 40 day or more) treatment assays. The results of this
study remove one of the obstacles for identification of
effective and safe compounds to treat Chagas disease.
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from the pPT7:O
tet/Luc vector (a gift from John E. Donelson,
University of Iowa, Iowa City, IA). The primers used were flanked
by the appropriate Gateway Att recombination sites (bold italics)
and were as follows: luciferase sense primer; GGGACAAGTTTG-
TACAAAAAAGCAGGCTCAACCATGGfoAAGACGCCAAAA-
ACATAAAGAA, luciferase antisense primer; GGGGAC-
CACTTTGTACAAGAAAGCTGGGTCTTACACGGCGACT-
TTTCC GCCCTT CTTGG. The luciferase PCR fragment was
then cloned into the pDONR-221 vector (Invitrogen, Carlsbad,
CA) utilizing the Gateway Att recombination sites. A third vector
was generated with the 39UTR for the luciferase gene by
amplifying the T. cruzi Aldolase 39UTR sequence from the
original pLew90b plasmid with flanking Gateway Att recombina-
tion sites (bold italics): Aldolase 39UTR sense primer, GGGGA-
CAGCTTTCTTGTACAAAGTGGGGTCTTAAGGATCCTG-
CCCATT, Aldolase 39UTR antisense primer, GGGGA-
CAACTTTGTATAATAAAGTTGTGCCCGGGCTCGAAT-
CCC CCC. The Aldolase 39UTR fragment was then cloned into
the pDONR-P2RP3 vector (Invitrogen, Carlsbad, CA) utilizing
the Gateway Att recombination sites. Finally, the pLew90b-GW-
T7 (Destination) plasmid, pDONR-P4P1R/T7/PARP SAS,
pDONR-221/luciferase, and pDONR-P2RP3/Aldolase 39UTR
plasmids were combined as per the Multi-Gateway protocol
(Invitrogen Carlsbad, CA) to yield a final plasmid construct of
pLew90b-GW/T7/PARP SAS/luciferase/Aldolase 39UTR
(Figure 1B). This vector was transfected into T. cruzi epimastigotes
using the same protocol as described above for the tdTomato
vector.
Epimastigote growth inhibition assay
tdTomato epimastigotes (1610
4 parasites/well) were plated in
96 well Costar black plates (Corning Incorporated, Corning, NY)
with or without drug and the change in fluorescence intensity was
measured as surrogate of growth using a fluorescence plate reader
(SpectraMax M2, Molecular Devices, Sunnyvale, CA) daily for 4
days. Benznidazole (RadanilH, Roche, Rio de Janeiro) tablets
(100 mg) were pulverized, dissolved in nanopure (Milli-Q) water,
then filter sterilized and used as the reference trypanocidal drug
(positive control). EXO2 derivatives [29–32] (EXO2-04, EXO2-
12, EXO2-17 and EXO2-36) were kindly provided by Jose C.
Aponte and Gerald B. Hammond (University of Louisville,
Louisville, KY) and were dissolved in DMSO, with a final
concentration containing less than 0.1% DMSO per well. The
50% inhibitory concentration (IC50) values were determined by
linear regression analysis on day 3 of culture.
Amastigote growth inhibition assay
Vero cells were exposed to 2000 rad of gamma radiation for ten
minutes [33] and 1.7610
4 cells were plated in 96-well plates
overnight at 37uC/5% CO2. Vero cells were exposed to
trypomastigotes of the CL tdTomato strain of T. cruzi for
approximately 5 h at a multiplicity of infection (MOI) of 10.
After infection, cell cultures were washed to remove non-
internalized parasites and fresh media with or without benznida-
zole (as the reference trypanocidal drug) or test compounds were
added. The change in fluorescence intensity was determined as a
measurement of growth over 3–4 days of culture. The 50%
inhibitory concentration (IC50) values were determined by linear
regression analysis at day 3.
In vivo drug testing of anti-T. cruzi compounds
Balb/c mice were purchased from the National Cancer Institute
(Frederick, MD) and maintained in the University of Georgia
animal facility in microisolator cages under specific pathogen-free
conditions. For the short term in vivo assay mice were infected in
each pad of both hind feet with either 2.5610
5 of T. cruzi
trypomastigotes (CL strain) expressing the tdTomato protein or
with 1610
5 trypomastigotes expressing luciferase. Mice were then
submitted to benznidazole (BZ), ENH-5 and NTLA-1 (nitrotria-
zole derivatives; the gift of Maria Papadopulou, Northwestern
Medical Center), Posaconazole, an antifungal triazole derivative
(POS) [34], EXO2-04, or BIS767 (a bisphosphonate; the gift of
Melina Galizzi and Roberto Docampo), treatment from day 6 to
day 11 (tdTomato parasites) or from day 4 to day 10 (luciferase
parasites) post infection. An untreated control, as well as a naı ¨ve
Figure 1. Plasmids used in the generation of fluorescent and bioluminescent T. cruzi. Schematic representation of (A) the pTrex-Neo-
tdTomato plasmid, and (B) the pLew90b-GW/T7/PARP SAS/luciferase/Aldolase 39UTR plasmid used for generation of the T. cruzi reporter lines.
doi:10.1371/journal.pntd.0000740.g001
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experiment. BZ was prepared by pulverization of one tablet
containing 100mg of the active principle, followed by suspension
in distilled water. BZ was administered orally, with daily doses of
100 mg/kg body weight. ENH-5 (20mg/kg/day) and NTLA-1
(2mg/kg/day) were suspended in PBS and daily injected
intraperitoneally (i.p.) into mice while EXO2-04 (20mg/kg/day)
was suspended in 1% DMSO and administered to the mice i.p.
POS was dissolved in an aqueous solution of 2% methylcellulose
and 0.5% Tween 80 and administered orally, with daily doses of
20 mg/kg body weight. BIS767 was suspended in PBS and daily
injected subcutaneously into mice. The fluorescence and biolumi-
nescent intensity (photons/cm
2/sec) was measured before and
after treatment as a surrogate of parasite load at the site of
infection.
For the long term in vivo assay mice were infected i.p. with 1000
trypomastigotes of CL strain of T. cruzi and sacrificed by CO2
inhalation at different time points post infection. Infected mice
were divided into the following groups: mice infected without
specific treatment (untreated); mice treated orally with BZ, with
daily doses of 100 mg/kg body weight for 40 days (15 to 55 dpi)
(BZ40), mice treated with daily i.p doses of 2mg/kg/day of NTLA-
1 for 50 days (15–65 dpi), mice treated orally with POS for 40 days
(15–55 dpi) with daily doses of 20mg/kg/day (POS) and mice
treated subcutaneously with BIS767 for 30 days (15–45 dpi) with
daily doses of 500mg/kg/day (BIS767).
In vivo bioluminescent and fluorescent imaging
Prior to bioluminescent imaging, mice were anaesthetized with
1.5% isofluorane and then injected with 150 mg/kg body weight
of substrate luciferin potassium salt (Caliper, Hopkinton, MA)
dissolved in PBS was administered by a single i.p. injection. Mice
were imaged in a bioluminescent imaging system (IVIS 100;
Xenogen, Alameda, CA). Briefly, mice were placed into the
camera chamber, where a controlled flow of 1.5% isofluorane in
air was administered through a nose cone via a gas anesthesia
system. The luciferin substrate was allowed to adequately
disseminate in the mice [35] for 10 min before imaging. Mice
were imaged in dorsal, position by capturing a grayscale body
image overlaid by a pseudocolor image representing the spatial
distribution of the detected photons. Images were collected with
5 min integration time. Data acquisition and analysis were
performed by using the Living-Image software (Xenogen,
Alameda, CA) where luminescence could be quantified as the
sum of all detected photon counts per second within a chosen
region of interest. For in vivo fluorescent imaging, footpads of mice
subcutaneously infected with 2.5610
5 tdTomato parasites in 4 ul
were imagined every other day using the Maestro2 In Vivo Imaging
System (CRi, Woburn, MA) with the green filter set (acquisition
settings: 560 to 750 in 10 nm steps; exposure time 88.18 ms and
262 binning). Collected images were unmixed and analyzed with
the Maestro software v2.8.0A.
Statistical analysis
Statistical analysis was performed by ANOVA and unpaired T
test, using the GraphPad PRISM 3.0 software. Differences
between two groups were considered significant at p,0.05.
Results
Stable tdTomato expression in T. cruzi
The tdTomato gene used in these studies was generated by
genetically fusing two copies of the gene encoding the Tomato
Red Fluorescent protein to create a tandem dimer (td) named
tdTomato [25]. This construct possesses many desirable properties
relative to previously studied fluorescent proteins, including a
faster and more complete maturation and increased brightness
[25,35]. In addition, the tdTomato fluorescence signal can be
detected at $620 nm (outside the range of of the bulk of animal
tissue autofluorescence), which minimizes autofluorescence and
greatly increases the penetration of fluorescence signals into the
tissues [25,36]. The expression vector pTrex-Neo [26], carrying
the T. cruzi ribosomal promoter, has been shown to provide strong
protein expression in T. cruzi and to enable the stable integration
of exogenous genes into the ribosomal locus [26,37–38]. Thus the
gene encoding tdTomato was cloned into pTrex-Neo and the
pTREX-Neo-tdTomato (Figure 1A) construct transfected into
epimastigotes of various T. cruzi strains, which were then drug-
selected as described in the Materials and Methods. Parasite
fluorescence was monitored by microscopy and flow cytometry
(Figure 2A–B). Transfectant parasites expressing the tomato
protein showed a bright red fluorescence distributed throughout
the cell in all life cycle stages (Figure 2A). Moreover, the
fluorescence was stable in the absence of antibiotic pressure for
.5 months (Figure 2B).
In vitro drug screening assay
Extracellular epimastigotes are easily obtained and thus are
often used as a first step in the screening of new potential anti-T.
cruzi drugs in vitro [39]. To address whether fluorescent tdTomato
parasites were useful to screen for such compounds, we plated
tdTomato epimastigotes with or without the proven anti-T. cruzi
compound benznidazole (BZ) and the fluorescence intensity as a
representative of parasite growth was measured daily. A dose
dependent decrease in parasite growth was evident within 2 days
of addition of BZ to cultures and was clearly evident throughout
the remainder of the 4 day assay period (Figure 3A). The IC50
calculated for benznidazole is similar to that of other methods,
including visual counting (Figure 3A), and as previously reported
in the literature for several T. cruzi strains [40–41]. This method
showed low intra-assay variation and a very good consistency by
the inter-assay analysis (Figures 3B). The analysis of the test EXO2
compounds (EXO2-04, EXO2-12, EXO2-17 and EXO2-36)
revealed one with IC50 below than that of BZ (Figure 3C).
The ability of compounds to inhibit the intracellular growth of
T. cruzi amastigotes is a more rigorous and relevant test of anti-T.
cruzi activity, as it is applied to a stage which is the predominant
form in mammals and because the killing assay requires that drug
also cross the host cell membrane. Amastigote growth assays in
Vero cells worked similarly to epimastigotes assays, with parasite
fluorescence increasing over the 4 day culture period. BZ
exhibited a dose-dependent inhibitory effect on parasite growth
(Figure 4A). Furthermore, this assay produced comparable results
in 96 or in 384 well plates (Figure 4B–C), demonstrating the
potential utility for the testing of large compound libraries. Lastly,
the expression of tdTomato in different parasite strains which may
differ in susceptibility to various drugs provides an easy method to
confirm the susceptibility of multiple parasite strains to potential
anti-T.cruzi compounds (Figure 4C).
Use of tdTomato- and luciferase-expressing T. cruzi for
determination of drug efficacy in vivo
We next explored the utility of T. cruzi lines expressing firefly
luciferase or tdTomato for assessing the activity of compounds on
the in vivo growth and survival of T. cruzi. In order to optimally
visualize parasite development as well as to simulate a normal
route of infection, parasites were delivered subcutaneously into the
footpad of mice. Mice were then left untreated or were treated
New Methods for Testing of Anti-T. cruzi Compounds
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infected with tdTomato parasites or 4 days post infection for mice
infected with bioluminescent parasites. These time points were
chosen as they allowed sufficient time for establishment of the
infection and easy visualization using the respective imaging
technique. In addition to the proven compound BZ, a number of
other compounds were tested with either assay, including EXO2
which had shown excellent IC50 in the in vitro assay (Figures 3 and
4), NTLA-1 and ENH-5, two nitrotriazole derivatives also
previously demonstrated to have high in vitro activity against T.
cruzi amastigote growth (M. Papadopoulou personal communica-
tion), a bisphosphonate (BIS767) with in vitro anti-T. cruzi activity
(Galizzi and Docampo personal communication) and the antifun-
gal posaconazole (POS), which has been reported to have in vivo
trypanocidal activity [22,42]. In all cases the compounds were
delivered systematically, by oral gavage in the case of BZ and POS
and by i.p. injection in the cases of the EXO2-04, NTLA-1 and
ENH-5 and by a subcutaneous injection in the ventral abdomen in
the case of BIS767.
Both the tdTomato and the luc-based assays revealed a rapid in
vivo parasite clearance activity for BZ and POS, with dramatic
control of parasite load within 1 day with BZ and slightly longer in
the case of POS (Figures 5 and 6). In contrast, none of the other
test compounds exhibited significant effects on in vivo parasite
growth, despite their previously demonstrated in vitro anti-T. cruzi
activity.
Suppression of parasitemia is not indicative of parasite
clearance
In previous work, we showed that BZ treatment in the acute or
chronic phase of the infection can provide cure of mice infected
with T. cruzi [43]. We sought to explore whether the same
compounds used in the in vivo short term assays were effective to
cure mice infected with T. cruzi. To address this question, C57BL/
6 mice were infected with the wild-type CL strain of T. cruzi and
treated with either BZ, POS, NTLA-1 or BIS767 or left untreated.
All mice exhibited detectable parasitemias by day 14 post-
infection; in untreated mice this acute phase parasitemia peaked
at 21 dpi and became undetectable by approximately 35 dpi
(Figure 7A). All of the compounds evaluated in this study
suppressed parasitemia, which became undetectable in all cases
by 21 dpi (Figure 7A). However, only the mice treated for 40 days
Figure 2. Fluorescence evaluation of tdTomato parasites. (A) Microscope image showing the tdTomato expressing parasites in all the life
stages. (B) The fluorescence intensity in epimastigotes was assessed using a CyAn flow cytometer (DakoCytomation) and analyzed with FlowJo
software (Tree Star). No decrease in fluorescence intensity was observed in parasites cultured for .5 months with (red) and without antibiotic (blue).
The background fluorescence of WT parasites (green) can also be observed.
doi:10.1371/journal.pntd.0000740.g002
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benznidazole at the indicated concentrations and comparison of measurement of drug inhibition of epimastigote growth by fluorescence and visual
counting by hemacytometer. (B) Intra-assay analysis (left) showing the low variation among wells with the same drug concentration (n=4). Inter-
assay analysis (right) showing the low variation among IC50 curves from individual assays. (C) IC50 calculation in response to benznidazole and the
EXO2 derivatives activity against epimastigotes after 3 days of treatment/culture.
doi:10.1371/journal.pntd.0000740.g003
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NLTA-1-treated mice (20%) were able to clear the infection and
cure, as by the failure to detect parasitemias after cyclophospha-
mide (cy) immunosuppression (Figure 7B). These results demon-
strate that suppression of parasitemia soon after drug-treatment
initiation Figure 7A) is a poor indicator of drug efficacy and the
potential for a compound to achieve parasitological cure over a
long-term course of treatment. Moreover, the results of the long-
term-treatment assay and the short-term in vitro screens using
measurement of parasite growth in the foot-pad following the
injection of luminescent or fluorescent T. cruzi (Figures 5 and 6) are
perfectly concordant, suggesting that the short-term in vivo assay is
strong predictor of in vivo drug efficacy and clearly superior to
measuring suppression of parasitemia.
Discussion
There is a clear need for new compounds to treat T. cruzi
infection at all stages of the infection/disease [3,6,44–45]. One
crucial limitation in the identification of such compounds is the
lack of adequate and efficient in vitro and in vitro tests of drug
efficacy. Various colorimetric and fluorometric assays have been
developed to screen for anti-T. cruzi compounds [7–12] which are
more accurate and objective than the microscopic visual counting.
More recently, an efficient method to quantify T. cruzi parasites in
drug screening assays using genetically engineered parasites that
express the Escherichia coli b-galactosidase gene, lacZ has been
described [15]. Although widely and effectively used and even
scaled to a 384 well format (Ana Rodriguez, personal communi-
cation), this method depends on a single endpoint reading
following the addition of detergent and a convertible substrate.
T. cruzi lines expressing alternative reporters such as luciferase
[46], fluorescent proteins [37,47] have also been produced, but the
use of these parasites lines for in vitro and in vivo screening of
potential anti-T. cruzi compounds has not been reported.
Herein, we report the generation of stable T. cruzi lines
constitutively expressing the tandem tomato fluorescence protein
(tdTomato) or the firefly luciferase protein and the use of these
lines to screen for anti-T. cruzi compounds in vitro and to confirm
their activity in vivo. tdTomato-expressing parasites showed strong
fluorescence in all life stages including when the parasites were
maintained in the absence of antibiotic selection. Among the
advantages of the use of these fluorescent parasites for in vitro
assays is the elimination of the need for fixation or cell
permeabilization, and detection of fluorescence with minimal
handling using a fluorimeter, microscope-based screener or other
imaging system. The use of fluorescent parasites also allows for the
continuous measurement of parasite replication during the
experiment, making possible the analysis of the parasite growth
and/or the initiation and cessation of growth inhibition by drugs
over time. The fluorescence-based growth inhibition assays of both
epimastigotes and intracellular amastigotes had high intra- and
inter-assay consistency and could be easily scaled to at least a 384
well format, allowing for the development of high throughput
screening of large compound libraries. The assays also work well in
multiple T. cruzi strains; to date we have produced TdTomato
expressing parasites from all 4 T. cruzi lines in which we have
attempted.
While the in vitro drug screening assay is a significant
improvement in methodologies for testing of anti-T. cruzi
compounds, the use of T. cruzi lines expressing luciferase and
tdTomato for in vivo compound screening bridges a more
significant technical gap and thus represent a much bigger step
forward. The current standard for the in vivo testing of anti-T.
cruzi compounds is the measurement of the suppression of
parasitemia in the acute phase of the infection or the protection
from acute-phase death, neither of which assess parasitological
cure [18–22]. We have recently developed an in vivo treatment
protocol that critically evaluates parasitological cure by using
suppression of immune responses following drug treatment, a
procedure that releases constraints on parasite growth and thus
reveals drugs and treatment regimens that fail to completely cure
the infection [43]. In this study, we have used this immunosup-
pression technique as the gold standard for drug-induced cure.
However, the considerable drawback of this protocol is the long
course of the experiment, including ,40 days for compound
treatment and a minimum of 75–80 days for the entire
experiment. Herein we demonstrate that a short-term treatment
protocol, involving 5–6 days of treatment and a total of 11–12 days
for the full experiment, that assesses the suppression of parasite
replication (although not full clearance) at subcutaneous sites. The
assay is not only quick, but is also quite easy, requiring short-term
compound dosing and occasional animal imaging. Most impor-
tantly, for the limited set of compounds tested to date, this short-
term assay using either bioluminescent or fluorescent parasites
gives results that are nearly identical to those obtained using the
long-term treatment protocol followed by immunosuppression; In
both assays BZ is most highly effective compound of those tested
and POS is slightly less effective.
A particularly notable point from the results of these different
screening assays is that multiple compounds that strongly suppress
epimastigote and amastigote growth in vitro, and furthermore,
rapidly and significantly suppress the level of parasites in the blood
of acutely infected mice, fail to cure mice in the long term
treatment assays or to suppress parasite replication in the tissues in
the short-term assay. Although more compounds will have to be
compared using both the short- and long-term in vivo protocols
used herein, the results to date are highly encouraging that the
short-term assay measures a drug effect that is more like what is
required for parasitogical cure and thus is a better screen for in
vivo efficacy than the acute suppression of parasitemia. Certainly,
these two assays are likely measuring very different parameters,
with suppression of parasitemia highlighting drugs that may have
anti-parasite effects largely or solely on extracellular parasites. It is
especially interesting that compounds that clearly suppress
intracellular parasite replication in vitro fail to control parasite
growth in the short term in vivo assays, despite the fact that the
parasites are largely intracellular during these short-term in vivo
tests (as they would have to be if they are increasing in number as
indicated by the increase in fluorescent signal over time).
Although the short-term in vivo assay is quick and straightfor-
ward, there may also be room for additional improvements. A
common limitation of these assays is the inability of fluorescent or
bioluminescent signals to easily penetrate animal tissues, including
fur. For this reason, we monitored parasite growth in subcutane-
ous hairless sites (footpads (shown here)) and ears (data not shown),
Figure 4. In vitro amastigote growth assays using tdTomato parasites. (A) Amastigotes growth in Vero cells grown in 96 well plates over time
in the presence of benznidazole (n=8). (B) Comparison of IC50 calculations in response to EXO2-04 in 96 and 384 well plates at 3 days of treatment
(n=4). (C) Amastigote growth assay in 96 or 384 well plates using the Colombiana and TCC strain of T. cruzi expressing tdTomato fluorescent protein
at 3 days of treatment (n=8).
doi:10.1371/journal.pntd.0000740.g004
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pads with 2.5610
5 T. cruzi tdTomato trypomastigotes and the images were taken every two days from day 1 to 11 post infection. (A) Images from
days 5, 7 and 9 post infection. (B) Quantification of the fluorescent signal from mice in panel A at all imaging points.
doi:10.1371/journal.pntd.0000740.g005
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5
T. cruzi bioluminescent trypomastigotes. For all images shown the color scale ranges from blue (with a minimum set at 60 photons/s/cm
2/sr) to red
(maximum of 3000 photons/s/cm2/sr). (B) Quantification of luminescent signal from mice in panel A.
doi:10.1371/journal.pntd.0000740.g006
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throughout the body when infections are given at higher doses
and/or at later time points in the infection (data not shown and
[46]). The sensitivity of detection of the luciferase-expressing
parasites is greater than that of the tdTomato parasites. However
this advantage is surpassed by the fact that visualization of the
tdTomato parasites does not require the repeated injection of the
luciferase substrate nor a requirement to control for the time post-
substrate injection that the imaging is done. Given that the
beneficial effects of both BZ and POS are obvious within a day or
2 post-administration, it is also possible that the identification of
drugs equivalent in efficacy to BZ may require only a single
Figure 7. Rapid suppression of parasitemia following drug-treatment is a poor indicator of drug efficacy and parasitological cure.
(A) Evolution of parasitemia after infection with 1610
3 CL strain of T. cruzi on day 0 in untreated (&), BZ-40 (n), POS (#), NTLA-1 (m), or BIS767 (%)
treated mice. ‘‘BIS767, BZ-40, POS and NTLA-1’’ bars below x axis indicate period of treatments. (B) Parasitemias in untreated or treated mice at
120dpi, after administration of the immunosuppressant cyclophosphamide (cy) (days 105, 108, 111, 113 and 117).
doi:10.1371/journal.pntd.0000740.g007
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time points. These modifications would make it possible to screen
100’s of compounds in vivo in very short order. Compounds that
give a positive result could then be submitted to the longer-term
treatment/immunosuppression assay.
The focusing of parasites largely at the site of infection was also
evident in these experiments and contributed to the success of this
technique for assessing drug treatments. The imaging of the
luciferase or tdTomato parasites is not sufficiently sensitive to
detect the movement of small number of parasites from the
subcutaneous injection point to other distant sites. However it is
clear that the vast majority of parasites remain at the injection site,
where they infect cells and replicate. Interestingly, even in the
absence of drug treatment, parasite load at the site of injection
diminishes after ,10 days post infection. Preliminary results
suggest that this reduction is immune mediated, as it does not
occur in mouse strains with defects in T cell responses, and suggest
that whole animal imagining of parasite growth and dissemination
might also be useful in the study of immune control of T. cruzi at
tissue sites Padilla, et al, unpublished).
The tools described in this paper were dependable, facile and
low cost and provide new methods for the rapid screening of anti-
T cruzi compounds in vitro and in vivo. These methods should make
feasible the broader and higher-throughput screening programs
needed to identify potential new drugs for the treatment of T. cruzi
infection.
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